Tina’s Wish is announcing the launch of a new program, the Acceleration to Clinic (“A2C”) Grant. The A2C Grant is designed to provide integrated grant funding and expert advisory resources to investigator teams whose ovarian cancer-specific biomarkers have achieved a defined level of clinical readiness as measured by the National Cancer Institute’s Early Detection Research Network (EDRN) five-phase biomarker development framework. These advisory resources strengthen translational decision-making, de-risk development pathways, and better position projects for successful clinical advancement and external funding. The A2C grant awards $1M in total costs over 2 years. The application cycle is now open.
Key Dates
- LOI application deadline: September 9, 2026 *
- Full application invitation: October 26, 2026
- Full proposal submission deadline: December 15, 2026
- Finalist presentations: March 29, 2027 (tentative)
- Notification of award: April 5, 2027
- Start of Year 1 funding: July 1, 2027
A2C LOI Guidelines – Click Here
A2C Full Application – By Invitation Only